Dermatofibrosarcoma protuberans

Exam relevance: in 4 of more than 50 board exam reports · rank 33

Synonyms
DFSP
Specialty
Dermatology · Skin tumours
Images
Clinical 1 · Histology 2
In the app
8 flashcards
Last updated
10/2026 · Dr. Pascal Bafteh
Contents
  1. Images (3)
  2. Definition
  3. Classification
  4. Clinical features
  5. Diagnosis
  6. Differential diagnoses
  7. Treatment principles
  8. Keep learning in the app
  9. References (selection)
  10. Cross-references

Images (3)

Dermatofibrosarcoma protuberans – clinical photo: firm, reddish-violaceous nodular tumor on the upper lip
firm, reddish-violaceous nodular tumor on the upper lip.Tontonflingueur, “Dermatofibrosarcome facial 01”, CC BY-SA 4.0, via Wikimedia Commons · CC BY-SA 4.0 · Source
Dermatofibrosarcoma protuberans – histology (H&E): monomorphic spindle cells infiltrating subcutaneous fat in a honeycomb patternHistology
histology (H&E): monomorphic spindle cells infiltrating subcutaneous fat in a honeycomb patternLWozniak&KWZielinski, “SkinTumors-P9280838”, CC BY-SA 3.0, via Wikimedia Commons · CC BY-SA 3.0 · Source
Dermatofibrosarcoma protuberans – histology (H&E): storiform (cartwheel) pattern of monomorphic spindle cellsHistology
histology (H&E): storiform (cartwheel) pattern of monomorphic spindle cellsNephron, “Storiform pattern - high mag”, CC BY-SA 3.0, via Wikimedia Commons · CC BY-SA 3.0 · Source
1 / 3

Definition

Definition & Epidemiology

  • Most common sarcoma of the skin, fibroblastic differentiation with (myo-)fibroblastic components.
  • Average age: ~ 40 years, slow destructive local growth.
  • Metastasis is rare – figures differ: Braun-Falco (2018, p. 1896) gives under 5 % (regional lymph nodes and lung), DermNet NZ about 5 % (roughly 1 % lymphatic, 4 % haematogenous, most often to the lung). A systematic review found metastases in 1.1 % of classic DFSP but in 14.4 % of tumours with fibrosarcomatous transformation (Liang et al. 2014); Braun-Falco likewise gives 15 % for dedifferentiated variants.

Classification

Sub-Variants

  • Classic DFSP — as above.
  • Bednar tumor (pigmented DFSP variant): melanin-containing dendritic cells.
  • Fibrosarcomatous DFSP transformation (DFSP-FS): Dedifferentiation + Mitosis ↑.
  • Giant cell fibroblastoma: pediatric variant, same COL1A1-PDGFB translocation.

Clinical features

Clinical Presentation

  • Location: trunk-predominant (~ 50 %), proximal extremities, shoulders; rarely head and neck.
  • Appearance: brownish-livid plaque.
  • Course: Years of unremarkable plaque-stage progression until nodular manifestation; destructive-infiltrative, R0 resection technically challenging due to tentacular subcutaneous extensions.

Diagnosis

Diagnostics

  • Clinical presentation + ultrasound of the primary tumor (depth of extension, hypoechoic-heterogeneous).
  • MRI in case of suspected deep infiltration (subcutis, fascia).
  • Immunohistochemistry: CD34+, F XIIIa− for differentiation from dermatofibroma (= XIIIa+).
  • Molecular: FISH or RT-PCR for COL1A1-PDGFB fusion to confirm difficult cases (e.g., fibrosarcomatous variant).
  • Staging: Whole-body examination + ultrasound of regional lymph nodes; cross-sectional imaging (CT/MRI) for DFSP-FS, very extensive tumours, local recurrence or suspected metastases.

Differential diagnoses

Image credits for the thumbnails
  • Dermatofibroma: Jmarchn, “Pigmented and tenderness dermatofibroma”, CC BY-SA 3.0, via Wikimedia Commons · CC BY-SA 3.0 · Source
  • Lipoma: James Heilman, MD, “LipomaBack”, CC BY-SA 3.0, via Wikimedia Commons · CC BY-SA 3.0 · Source
  • Epidermal cyst (atheroma): unknown (Commons user), “Epidermal Cyst ear”, CC BY-SA 3.0, via Wikimedia Commons · CC BY-SA 3.0 · Source
  • Basal cell carcinoma: Bin im Garten, “Basaliom am Nasenrücken 2”, CC BY-SA 3.0, via Wikimedia Commons · CC BY-SA 3.0 · Source
  • Melanoma: National Cancer Institute (unknown photographer), “Melanoma (4)”, Public Domain, via Wikimedia Commons · Public domain · Source
  • Kaposi's sarcoma: unknown author, “Kaposi's Sarcoma”, Public Domain, via Wikimedia Commons · Public Domain · Source
  • Cutaneous angiosarcoma: Messias H, Martins M, Zagalo C et al. (Cancer Rep (Hoboken) 2022), CC BY 4.0, via PubMed Central (PMC9575495) · CC BY 4.0 · Source

Treatment principles

  • The treatment of choice is micrographically controlled surgery including the fascia; if this is not available, wide local excision is performed.
  • Radiotherapy is an option for primarily inoperable tumours, for residual tumour when re-excision is not possible and after multiple recurrences; after complete removal no adjuvant irradiation is given.
  • Locally advanced, inoperable or metastatic tumours can be treated with a tyrosine kinase inhibitor; because late recurrences occur, long-term follow-up is required.

Guideline: AWMF guideline register (no. 032-026)

Specific treatment regimens with drugs and doses are covered in the DermaFuchs app.

Keep learning in the app

In the DermaFuchs app you can learn Dermatofibrosarcoma protuberans with flashcards, exam questions and spot-the-diagnosis – free, in your browser or as an app.

Test yourself: Spot-diagnosis quiz with real cases →

In the app: 8 flashcards

Open in browser  Download on the App Store

References (selection)

  1. Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline

Cross-references

Keep learning: test yourself

Two questions from the DermaFuchs app on Dermatofibrosarcoma protuberans – tap an answer.

Question 1 of 2

What is the immunohistochemical profile of dermatofibrosarcoma protuberans (DFSP)?

Answer

Correct: CD34+, CD99+, Factor XIIIa−. DFSP typically shows positivity for CD34 and CD99, and negativity for Factor XIIIa, aiding in its diagnosis.

Question 2 of 2

What is the typical appearance of Dermatofibrosarcoma protuberans?

Answer

Correct: brownish-livid plaque. Dermatofibrosarcoma protuberans typically appears as a brownish-livid plaque.

More questions like these – with explanations and spaced repetition – in the app.

Note: This page is intended for medical education and does not replace diagnosis or treatment decisions in individual cases.